Is Liposomal Urolithin A Better Absorbed? What the Evidence Actually Shows

Urolithin A has earned serious scientific attention for its ability to support mitophagy: the cellular process by which damaged mitochondria are identified and cleared, making room for healthier replacements. This mechanism underpins much of the interest in urolithin A as a compound for muscle health, cellular aging, and metabolic function. But how well your body actually absorbs and uses urolithin A matters enormously, and a growing number of supplement manufacturers have begun marketing liposomal versions, claiming they deliver the compound more efficiently.

Before assuming liposomal means better, it is worth examining what the research actually says. The science of urolithin A delivery is still maturing, and while there is genuine evidence that encapsulation technologies can improve bioavailability in laboratory settings, clinical data in humans remains limited. This article walks through the current evidence honestly, explaining what liposomes are, what studies have found, and what remains unknown.

Why Urolithin A Absorption Is a Real Challenge

Urolithin A is a polyphenol-derived compound that many people do not produce efficiently on their own (in a trial of 100 US adults, 33% made none and another 27% made little from pomegranate juice) ^[7][8]. It requires specific gut bacteria to convert ellagitannins (found in pomegranates, walnuts, and certain berries) into urolithin A, and gut microbiome composition varies widely between individuals. Research has highlighted that this variability in gut conversion, combined with the compound’s own physicochemical properties, makes oral bioavailability inconsistent and often low ^[5].

As a small lipophilic molecule, urolithin A is poorly soluble in water. Once ingested, it must survive the gastrointestinal environment, be absorbed through intestinal membranes, and reach systemic circulation in sufficient concentrations to exert biological effects. Studies examining how the compound behaves after oral dosing note that its stability across different pH environments and its ability to cross mucosal barriers are both meaningful hurdles ^[1]. This is the core problem that encapsulation technologies aim to solve.

What Liposomal Delivery Actually Does

Liposomes are spherical vesicles made from phospholipid bilayers: essentially the same material as cell membranes. When a compound like urolithin A is encapsulated inside a liposome, it is shielded from the acidic conditions of the stomach and can be transported more intact to the small intestine, where absorption occurs. Liposomal delivery has been used for decades in pharmaceutical research to improve the bioavailability of drugs that are otherwise difficult to absorb.

For urolithin A specifically, a 2023 study using a pH-driven liposome encapsulation method found that encapsulation improved stability, bioaccessibility, and bioavailability of urolithin A compared to unencapsulated forms ^[1]. The researchers compared liposomal and free urolithin A under simulated gastrointestinal conditions and reported that the liposomal form retained more of the compound through digestion and demonstrated higher bioaccessibility: the fraction that is potentially available for absorption from the gut. This suggests, in a laboratory model, that liposomal encapsulation can change how much urolithin A survives digestion; it is not evidence of higher blood levels in people ^[9][10].

It is worth noting that bioaccessibility and bioavailability, while related, are not identical. Bioaccessibility refers to how much of a compound is released and available for absorption in the gut; bioavailability refers to how much ultimately reaches systemic circulation. The 2023 liposome study addressed both, but as with much of this research, the work was conducted using in vitro and model systems rather than a clinical trial in humans.

Other Encapsulation Approaches Under Study

Liposomes are not the only delivery technology researchers are exploring for urolithin A. A 2025 study developed a submicron emulsion-based system to improve the compound’s anti-inflammatory activity, reporting that the emulsion format enhanced solubility and cellular uptake in experimental models ^[2]. Submicron emulsions work similarly to liposomes in that they create a lipid-based environment that can protect and shuttle a hydrophobic compound through the digestive tract, but they have a different structural architecture.

A 2026 study tested a biomimetic nanocarrier, a carboxymethyl β-glucan shell combined with a zeolitic imidazolate framework, and found it improved structural stability, controlled gastrointestinal release, and enhanced the antioxidant efficacy of urolithin A in cellular models, with effects mediated in part through the dectin-1 receptor and mitophagy pathways ^[3]. Separately, earlier work using polymeric nanoparticles to deliver urolithin A orally in a mouse model of kidney injury found that the encapsulated form was able to normalize cellular stress markers in a way that aligned with urolithin A’s known mitophagy-supporting mechanism ^[4].

A broader review of urolithin A delivery strategies in the context of cancer research has also highlighted that nanomedicine formulations (including liposomes, polymeric nanoparticles, and emulsions) can improve both stability and targeted delivery of the compound ^[6]. Taken together, the research direction is consistent: packaging urolithin A in a lipid-based or nanoparticle carrier tends to produce better performance in laboratory and preclinical models than free urolithin A. What remains less certain is the magnitude of this benefit in real-world human supplementation.

The Mechanism That Makes This Matter: Mitophagy and Mitochondrial Renewal

Understanding why bioavailability matters requires a brief explanation of what urolithin A is thought to do in the body. Its primary studied mechanism is the activation of mitophagy: a selective form of autophagy in which the cell identifies and degrades mitochondria that are damaged, dysfunctional, or no longer efficient. Healthy mitochondria are central to energy production, and as cells age, the proportion of damaged mitochondria tends to rise. Urolithin A appears to help clear this backlog, supporting a healthier pool of functional mitochondria ^[5].

For this process to occur, urolithin A must reach relevant tissues, particularly skeletal muscle, where mitochondrial quality is tightly linked to strength and endurance. If only a small fraction of an oral dose survives digestion and enters circulation, the dose that actually reaches muscle tissue may be insufficient to drive meaningful mitophagic activity. This is why delivery format is not merely a marketing question: the cellular effect size may depend directly on how much compound makes it to target tissues.

What the Evidence Does and Does Not Establish

The honest summary of the current evidence is this: liposomal and other encapsulation formats for urolithin A show meaningful improvements in stability and bioaccessibility in laboratory and preclinical models, and at least one study has directly compared liposomal urolithin A to unencapsulated urolithin A with favorable results for the liposomal form ^[1]. The broader literature on novel delivery systems supports the principle that encapsulation helps ^[2][3][4].

What the evidence does not yet establish is a clear clinical advantage in humans. There are no published randomized controlled trials directly comparing muscle, metabolic, or aging outcomes between liposomal urolithin A and a standard crystalline urolithin A supplement at equivalent doses in human participants. The nanoparticle and liposome studies cited here used in vitro digestion models, animal models, or cell-based assays. This is a meaningful gap. Some bioavailability improvements seen in model systems do not fully translate into equivalent clinical benefit in human trials.

Other caveats apply to the lab work. One rat study relayed in FDA’s GRAS letter reported low absorption (under 2.2%) of oral urolithin A, and a review notes that many in vitro urolithin studies did not use physiologically relevant forms and concentrations, which makes some reported activities questionable ^[14][10].

It is also worth acknowledging that some commercial urolithin A supplements, particularly those using a standardized crystalline form (MitoPure), have been tested in human clinical trials, which reported plasma and gene-expression biomarker changes and some secondary muscle measures but missed their primary endpoints ^[11][12][13]meaning a well-formulated standard supplement is not automatically inferior just because it lacks a liposomal wrapper. The question is whether liposomal formulations provide an additional advantage above that already established baseline, which has not yet been directly tested in clinical conditions ^[5].

Practical Implications for Supplement Consumers

If you are considering a liposomal urolithin A supplement, the scientific rationale for better absorption is real, not merely marketing language. Encapsulating a lipophilic compound in a phospholipid vesicle is a legitimate and well-studied pharmaceutical strategy, and the research on urolithin A specifically supports the concept that encapsulation improves how much of the compound survives digestion ^[1]. The gap in the evidence is not whether the mechanism is plausible, it is, but whether a given commercial liposomal product is manufactured with sufficient quality and correct vesicle size to deliver on that promise, and whether the human outcome benefit is materially greater than a standard supplement.

Factors worth considering include: the liposome particle size (smaller, more uniform liposomes tend to absorb better), the phospholipid quality used in manufacturing, the stability of the product over its shelf life, and the total dose of urolithin A per serving. A poorly manufactured liposomal product could underperform a high-quality standard supplement. In the absence of head-to-head clinical data, no one can tell you with certainty that any specific liposomal brand is better than a well-dosed crystalline alternative.

A Note on the Evidence

The studies cited here are largely preclinical, conducted in vitro or in animal models, and do not constitute proof of equivalent clinical benefit in humans. Urolithin A supplements are not intended to diagnose, treat, cure, or prevent any disease. If you have kidney disease, are taking medications, or have a chronic health condition, consult a qualified healthcare provider before adding any urolithin A supplement to your routine.

Frequently Asked Questions

What is urolithin A and why does absorption matter?

Urolithin A is a compound produced when gut bacteria metabolize ellagitannins from foods like pomegranates. Its primary mechanism of interest is mitophagy: the cellular clearance of damaged mitochondria. Because many people produce it poorly from diet alone, and because it has low water solubility that complicates oral absorption, the dose that reaches target tissues can be less than what is ingested ^[5][7][8]. Better absorption means more compound available to support mitochondrial renewal.

Has liposomal urolithin A been tested directly against standard urolithin A?

A 2023 study directly compared liposomal urolithin A (prepared by pH-driven encapsulation) to free urolithin A using in vitro digestion models. The liposomal form showed improved stability during simulated gastrointestinal digestion, higher bioaccessibility, and improved bioavailability ^[1]. This is the most direct comparison available, though it was conducted in model systems rather than in a human clinical trial.

Are there other delivery technologies besides liposomes being studied for urolithin A?

Yes. Research has examined submicron emulsions ^[2], polymeric nanoparticles ^[4], biomimetic nanocarriers combining β-glucan shells with metal-organic frameworks ^[3], and a range of other nanomedicine platforms ^[6]. All of these approaches share the goal of improving stability and intestinal absorption, and all show promise in laboratory or preclinical settings.

What is mitophagy and why does urolithin A's effect on it matter?

Mitophagy is a cellular housekeeping process in which the cell identifies mitochondria that are damaged or poorly functioning and tags them for degradation. This clears space and cellular resources for the generation of healthier mitochondria. As cells age, mitophagy tends to slow, allowing dysfunctional mitochondria to accumulate, which is associated with reduced cellular energy production. Urolithin A is believed to support mitophagy activation, making its absorption and tissue delivery relevant to whether the compound can exert its intended cellular effects ^[5].

Does a liposomal label guarantee better absorption from any given supplement?

Not automatically. Liposomal delivery is a legitimate pharmaceutical technology with real evidence behind it for urolithin A ^[1], but the quality of a liposomal product depends heavily on manufacturing, including phospholipid type, liposome particle size, encapsulation efficiency, and product stability over time. A poorly formulated liposomal supplement may not deliver the absorption advantages seen in controlled research settings. The label alone is not sufficient; quality and dose still matter.

Should I take liposomal urolithin A instead of a standard supplement?

This is a personal decision that should involve a healthcare provider, especially if you have any underlying health conditions. The scientific rationale for liposomal urolithin A improving absorption is credible and supported by laboratory research ^[1], but clinical trials comparing health outcomes between liposomal and standard urolithin A in humans have not yet been published. Both formats may provide benefit; the degree of difference in real-world practice remains uncertain.

References

1. Hu Y et al. Liposomes encapsulation by pH driven improves the stability, bioaccessibility and bioavailability of urolithin A: A comparative study. International journal of biological macromolecules (2023). PMID 37865359
2. Esposito E et al. Development of a submicron emulsion-based delivery system to improve the anti-inflammatory activity of urolithin A. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques (2025). PMID 41280710
3. Hu F et al. Biomimetic carboxymethyl β-glucan-ZIF-8 nanocarrier enhances structural stability, gastrointestinal release, and antioxidant efficacy of urolithin A via dectin-1-engaged mitophagy. Food research international (Ottawa, Ont.) (2026). PMID 41652714
4. Zou D et al. Oral delivery of nanoparticle urolithin A normalizes cellular stress and improves survival in mouse model of cisplatin-induced AKI. American journal of physiology. Renal physiology (2019). PMID 31532243
5. Yuan H et al. Urolithin A From Gut Metabolite to Therapeutic Agent: Bioavailability, Mechanisms, and Translational Insights. Journal of food science (2026). PMID 41866331
6. Karumuru V et al. Unveiling the potential of Urolithin A in Cancer Therapy: Mechanistic Insights to Future Perspectives of Nanomedicine. Nanotheranostics (2025). PMID 40568370
7. Singh A et al. Direct supplementation with Urolithin A overcomes limitations of dietary exposure and gut microbiome variability in healthy adults to achieve consistent levels across the population. European journal of clinical nutrition (2022). PMID 34117375
8. Francisco Abraham Tomás-Barberán et al. Ellagic Acid Metabolism by Human Gut Microbiota: Consistent Observation of Three Urolithin Phenotypes in Intervention Trials, Independent of Food Source, Age, and Health Status. Journal of Agricultural and Food Chemistry (2014). PMID 24976365
9. Mena P et al. Gastrointestinal stability of urolithins: an in vitro approach. European journal of nutrition (2017). PMID 26439723
10. García-Villalba R et al. Urolithins: a Comprehensive Update on their Metabolism, Bioactivity, and Associated Gut Microbiota. Molecular nutrition & food research (2022). PMID 35118817
11. Andreux PA et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature metabolism (2019). PMID 32694802
12. Singh A et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell reports. Medicine (2022). PMID 35584623
13. Liu S et al. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA network open (2022). PMID 35050355
14. U.S. Food and Drug Administration Agency Response Letter GRAS Notice No. GRN 000791. U.S. Food and Drug Administration (2018). source

These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.